vs
RadNet, Inc.（RDNT）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
RadNet, Inc.的季度营收约是VERACYTE, INC.的3.9倍（$547.7M vs $140.6M）。VERACYTE, INC.净利率更高（29.3% vs -0.1%，领先29.4%）。VERACYTE, INC.同比增速更快（18.5% vs 14.8%）。过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs 12.6%）
RadNet是美国领先的放射医疗服务企业，总部位于加利福尼亚州洛杉矶，是美国规模最大的独立固定地址诊断影像中心运营商，按网点数量及年度影像业务收入计均居行业首位。截至2025年，该公司在全美8个州持有或运营超400家影像中心，提供门诊诊断影像服务。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
RDNT vs VCYT — 直观对比
营收规模更大
RDNT
是对方的3.9倍
$140.6M
营收增速更快
VCYT
高出3.7%
14.8%
净利率更高
VCYT
高出29.4%
-0.1%
两年增速更快
VCYT
近两年复合增速
12.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $547.7M | $140.6M |
| 净利润 | $-597.0K | $41.1M |
| 毛利率 | — | 72.5% |
| 营业利润率 | 5.1% | 26.4% |
| 净利率 | -0.1% | 29.3% |
| 营收同比 | 14.8% | 18.5% |
| 净利润同比 | -111.2% | 704.8% |
| 每股收益（稀释后） | $0.00 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RDNTVCYT
| Q4 25 | $547.7M | $140.6M | ||
| Q3 25 | $522.9M | $131.9M | ||
| Q2 25 | $498.2M | $130.2M | ||
| Q1 25 | $471.4M | $114.5M | ||
| Q4 24 | $477.1M | $118.6M | ||
| Q3 24 | $461.1M | $115.9M | ||
| Q2 24 | $459.7M | $114.4M | ||
| Q1 24 | $431.7M | $96.8M |
净利润RDNTVCYT
| Q4 25 | $-597.0K | $41.1M | ||
| Q3 25 | $5.4M | $19.1M | ||
| Q2 25 | $14.5M | $-980.0K | ||
| Q1 25 | $-37.9M | $7.0M | ||
| Q4 24 | $5.3M | $5.1M | ||
| Q3 24 | $3.2M | $15.2M | ||
| Q2 24 | $-3.0M | $5.7M | ||
| Q1 24 | $-2.8M | $-1.9M |
毛利率RDNTVCYT
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% | ||
| Q1 24 | — | 64.5% |
营业利润率RDNTVCYT
| Q4 25 | 5.1% | 26.4% | ||
| Q3 25 | 5.2% | 17.4% | ||
| Q2 25 | 6.2% | -4.0% | ||
| Q1 25 | -5.1% | 2.5% | ||
| Q4 24 | 5.1% | 3.5% | ||
| Q3 24 | 7.4% | 10.4% | ||
| Q2 24 | 7.6% | 4.0% | ||
| Q1 24 | 2.6% | -4.8% |
净利率RDNTVCYT
| Q4 25 | -0.1% | 29.3% | ||
| Q3 25 | 1.0% | 14.5% | ||
| Q2 25 | 2.9% | -0.8% | ||
| Q1 25 | -8.0% | 6.2% | ||
| Q4 24 | 1.1% | 4.3% | ||
| Q3 24 | 0.7% | 13.1% | ||
| Q2 24 | -0.6% | 5.0% | ||
| Q1 24 | -0.6% | -1.9% |
每股收益（稀释后）RDNTVCYT
| Q4 25 | $0.00 | $0.50 | ||
| Q3 25 | $0.07 | $0.24 | ||
| Q2 25 | $0.19 | $-0.01 | ||
| Q1 25 | $-0.51 | $0.09 | ||
| Q4 24 | $0.08 | $0.07 | ||
| Q3 24 | $0.04 | $0.19 | ||
| Q2 24 | $-0.04 | $0.07 | ||
| Q1 24 | $-0.04 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $767.2M | $362.6M |
| 总债务越低越好 | $1.1B | — |
| 股东权益账面价值 | $1.1B | $1.3B |
| 总资产 | $3.8B | $1.4B |
| 负债/权益比越低杠杆越低 | 1.00× | — |
8季度趋势，按日历期对齐
现金及短期投资RDNTVCYT
| Q4 25 | $767.2M | $362.6M | ||
| Q3 25 | $804.7M | $315.6M | ||
| Q2 25 | $833.2M | $219.5M | ||
| Q1 25 | $717.3M | $186.1M | ||
| Q4 24 | $740.0M | $239.1M | ||
| Q3 24 | $748.9M | $274.1M | ||
| Q2 24 | $741.7M | $235.9M | ||
| Q1 24 | $527.0M | $209.2M |
总债务RDNTVCYT
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $834.6M | — |
股东权益RDNTVCYT
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $932.3M | $1.2B | ||
| Q1 25 | $898.1M | $1.2B | ||
| Q4 24 | $902.3M | $1.2B | ||
| Q3 24 | $895.3M | $1.2B | ||
| Q2 24 | $881.0M | $1.1B | ||
| Q1 24 | $873.0M | $1.1B |
总资产RDNTVCYT
| Q4 25 | $3.8B | $1.4B | ||
| Q3 25 | $3.7B | $1.4B | ||
| Q2 25 | $3.5B | $1.3B | ||
| Q1 25 | $3.3B | $1.3B | ||
| Q4 24 | $3.3B | $1.3B | ||
| Q3 24 | $3.3B | $1.3B | ||
| Q2 24 | $3.2B | $1.2B | ||
| Q1 24 | $3.0B | $1.2B |
负债/权益比RDNTVCYT
| Q4 25 | 1.00× | — | ||
| Q3 25 | 1.04× | — | ||
| Q2 25 | 1.18× | — | ||
| Q1 25 | 1.12× | — | ||
| Q4 24 | 1.13× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.17× | — | ||
| Q1 24 | 0.96× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $84.2M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | — | $48.8M |
| 自由现金流率自由现金流/营收 | — | 34.7% |
| 资本支出强度资本支出/营收 | — | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | — | $126.6M |
8季度趋势，按日历期对齐
经营现金流RDNTVCYT
| Q4 25 | $84.2M | $52.6M | ||
| Q3 25 | $52.8M | $44.8M | ||
| Q2 25 | $120.3M | $33.6M | ||
| Q1 25 | $41.5M | $5.4M | ||
| Q4 24 | $42.5M | $24.5M | ||
| Q3 24 | $57.4M | $30.0M | ||
| Q2 24 | $116.0M | $29.6M | ||
| Q1 24 | $17.1M | $-9.0M |
自由现金流RDNTVCYT
| Q4 25 | — | $48.8M | ||
| Q3 25 | — | $42.0M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $20.4M | ||
| Q3 24 | — | $27.7M | ||
| Q2 24 | — | $26.8M | ||
| Q1 24 | — | $-11.1M |
自由现金流率RDNTVCYT
| Q4 25 | — | 34.7% | ||
| Q3 25 | — | 31.8% | ||
| Q2 25 | — | 24.8% | ||
| Q1 25 | — | 3.1% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 23.4% | ||
| Q1 24 | — | -11.5% |
资本支出强度RDNTVCYT
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 2.2% |
现金转化率RDNTVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | 9.75× | 2.34× | ||
| Q2 25 | 8.33× | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | 7.96× | 4.80× | ||
| Q3 24 | 17.89× | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RDNT
| Commercial Insurance1 | $301.0M | 55% |
| Medicare1 | $129.2M | 24% |
| Capitation Arrangements | $31.9M | 6% |
| Health Care Other | $20.4M | 4% |
| Digital Health | $16.4M | 3% |
| Other | $15.2M | 3% |
| Medicaid1 | $14.0M | 3% |
| Workers Compensation Personal Injury1 | $12.3M | 2% |
| Health Care Management Service | $7.5M | 1% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
